Use access key #2 to skip to page content.
$55.93 -4.53 (-7.49%)
10/6/2008 4:00 PM

Celgene Corp (CELG)

CAPS Rating:
****

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

View All Commentary (CELG)

Recs

4

Avatar predfern (< 20) Submitted: 9/15/06 4:53 AM : Outperform Start Price: $40.93 CELG Score: 57.57

Revlimid growth for treatment of myeloma, mds and other cancers (18%).
Thalomid used for treatment of varions cancers and leprosy (59%).
Alkeran and Focalin (10%) myeloma and ovarian cancer, attention deficit hyperactivity disorder, resp.
Cash flow $62.7 million (twice net income)
Recent and expected approvals will lead to greater demand.

Report this Post Replies: 0 | Reply

Featured Broker Partners